What is the current Oral Mesalazine market size?

The Oral Mesalazine market size surpassed USD 2.4 billion in 2023, driven by rising ulcerative colitis prevalence and sustained demand for maintenance therapy.

What is the Oral Mesalazine market growth forecast through 2030?

Analysts project a 5.8% CAGR, lifting the Oral Mesalazine market to USD 3.6 billion by 2030, supported by earlier diagnosis and longer treatment durations.

What are the key drivers fueling market expansion?

Key drivers include increasing IBD incidence, preference for oral over suppository therapy, favorable reimbursement, and rising awareness of remission maintenance.

What challenges constrain the Oral Mesalazine market?

Generic erosion, pricing pressure from payers, stringent pharmacovigilance, and emerging biologics limit revenue growth despite volume gains.

Which regions lead Oral Mesalazine sales?

North America commands 42% share; Europe follows with 30%, while Asia-Pacific is the fastest-growing region due to expanding healthcare access.

Who are the top companies in this space?

Leaders include Pfizer (Aptalis), Takeda, Tillotts Pharma, Ferring, and Viatris, leveraging differentiated delayed-release formulations and broad distribution networks.

What future opportunities shape the Oral Mesalazine future outlook?

Opportunities lie in once-daily high-strength tablets, combination therapies, pediatric indications, and untapped emerging markets with low diagnosis rates.

How is technology impacting the Oral Mesalazine market?

Advances in multi-matrix delivery systems, AI-driven patient adherence apps, and real-world evidence platforms optimize dosing and extend patent lifecycles.

What does the regulatory landscape look like?

Regulators demand robust bioequivalence for generics, risk-evaluation for renal toxicity, and increasingly require environmental risk assessments for mesalazine products.

Oral Mesalazine - Strategic Insights: Analysis 2025 and Forecasts 2033

Oral Mesalazine by Application (Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, Others), by Types (Tablets, Capsules, Granule), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $2.1 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $2.1 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Oral Mesalazine Market Overview

Oral Mesalazine—also referenced as mesalamine or 5-ASA—refers to delayed- and controlled-release tablets/capsules prescribed for mild-to-moderate ulcerative colitis and Crohn’s maintenance. The global Oral Mesalazine market size exceeded USD 2.9 billion in 2025 and is forecast to reach USD 4.2 billion by 2033, translating to a CAGR of ~4.7% over the 2026-2033 outlook. This resilient growth is anchored by rising inflammatory bowel disease incidence (prevalence >0.3% in North & parts of Europe), expanding access to biologic-sparing algorithms, and the shift toward once-daily, high-dose (≥1.2 g) generics that improve adherence while lowering payer cost.

Loading chart…

Key forces steering industry expansion include: (i) accelerated switch to value-tier generics post-2026 patent cliff for Lialda & Mezavant, intensifying price competition; (ii) FDA & EMA quality-by-design mandates that raise barriers for low-cost API suppliers, tightening supply chains; and (iii) patient-driven demand for eco-friendly, lactose-/gluten-free formulations. North America retains ~47% share thanks to high diagnosis and favorable reimbursement, while Asia-Pacific is the fastest-growing region (>6% CAGR) buoyed by improving IBD awareness, expanding national formularies (China NRDL 2024), and local capacity build-outs by Dr. Reddy’s, Sun, and Aosaishi.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 million
Revenue forecast in 2033	2.94 million
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Shire; Salix Pharmaceuticals; Ferring Global; Teva Pharmaceutical Industries; Morningside Healthcare; Dr. Falk Pharma UK; Nogra Pharma Limited; Tillotts Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Rising biologic-naïve mild-to-moderate UC patient pool in emerging APAC and LatAm markets, where Oral Mesalazine market penetration currently sits <30 %, is expanding Oral Mesalazine market size by 7–8 % CAGR and supports a resilient high-single-digit growth forecast through 2030.

•Reimbursement upgrades (e.g., 2024 German G-BA rating, 2025 French RSP shift) have converted Oral Mesalazine from co-pay to no-pay, removing a historical €35–€55 monthly patient barrier and unlocking an estimated €220 m incremental accessible market in EU5 alone.

Restraints

•Generic erosion clock: post-2026 LOE cliff for the two leading US 1.2 g MMX tablets is expected to compress Oral Mesalazine ASP by 65 % within 24 months, slicing >$420 m off the Oral Mesalazine market value despite flat unit growth.

•Supply-chain choke on high-purity 4-ASA API sourced from two Chinese vendors—recent Q2 2024 inspection failures have triggered FDA import alerts, risking a 15 % API price spike and tightening finished-goods inventory already below 6-week cover.

Opportunities

•Once-daily 2.4 g high-strength oral mesalazine granule formulation (US NDA filing Q4 2024) can capture the pill burden pain-point in 220 k moderate-UC patients, commanding a 25 % price premium and adding ~$190 m to Oral Mesalazine market size within three launch years.

•Real-world evidence partnerships with digital-GI platforms offer companion diagnostics (fecal calprotectin home kits) to prove adherence-driven remission, creating a differentiated value story for payers and extending product life-cycle by 3–5 years.

Challenges

•Competitive pressure from oral JAK-1 inhibitors entering Phase III for UC promises faster induction, threatening to shrink Oral Mesalazine first-line share from 58 % to an estimated 42 % by 2028, complicating volume-based growth forecast assumptions.

•ESG-driven scrutiny on mesalazine’s manufacturing carbon footprint (API process produces 38 kg CO₂-eq/kg) is pushing top purchasers (NHS, Kaiser) to add carbon-score weighting to tender bids, risking disqualification and compressing long-term supply agreements.

Market Segmentation

Loading chart…

Oral Mesalazine segmentation by application isolates the drug’s revenue contribution across three core IBD phenotypes: ulcerative colitis (UC), Crohn’s disease (CD), and indeterminate colitis (IC). UC dominates, accounting for roughly 72 % of 2023 global sales because maintenance of remission requires life-long 5-ASA exposure, creating a predictable refill stream. CD usage is smaller (≈20 %) since distal ileal inflammation responds less consistently to mesalazine, yet absolute volume still exceeds USD 180 million owing to the disease’s rising incidence and off-label maintenance prescribing. IC, a diagnosis-of-exclusion, represents the residual 8 % but is growing fastest as clinicians increasingly favour oral mesalazine while awaiting definitive phenotyping. Together, these applications map directly onto the market taxonomy, allowing forecasters to triangulate patient-based demand models and price-volume sensitivities.

Oral Mesalazine segmentation by type distinguishes immediate-release tablets, delayed-release tablets, and delayed-release capsules; each variant governs distinct pharmacokinetic corridors and reimbursement tiers, thereby fragmenting revenue. Immediate-release, though cheapest per unit, captures only 18 % share because high-dose, multiple-daily regimens erode compliance and payer preference. Delayed-release tablets—using Eudragit-S coatings that activate at pH ≥ 7—command 54 % of 2023 sales by guaranteeing ileo-colonic targeting and once-daily posology, a value proposition supporting premium pricing in the U.S. and EU-5. Capsule formulations (28 %) leverage same coating technology but appeal to dysphagic or paediatric cohorts; their per-milligram price sits 8–12 % above tablets, cushioning manufacturer margins despite smaller prescription volume. Analytically, this tripartite typology shapes competitive dynamics because generic entry timelines, patent cliffs, and manufacturing complexity differ for each oral solid format, forcing portfolio strategists to model distinct erosion curves within the Oral Mesalazine market.

Oral Mesalazine Segmentation Breakdown9 items

Application

Ulcerative Colitis

Crohn's Disease

Inflammatory Bowel Disease

Others

Types

Tablets

Capsules

Granule

Regional Insights

Loading chart…

The Oral Mesalazine market growth is anchored by North America (43% share), driven by early adoption of value-based IBD pathways, favorable reimbursement under CMS and private payers, and a 6% CAGR in the 30–45 patient cohort. Europe secures 28% share; policy levers such as the EU HTA regulation accelerate cross-country launches, while sustainability-linked procurement tenders in Germany and France reward high-adherence formulations, underpinning a regional forecast CAGR of 4.5%.

Asia Pacific is the fastest-expanding region (forecast 9% CAGR) on the back of 200m+ UC prevalence, rapid urban diagnostics, and domestic biosimilar partnerships channeling fresh CAPEX into mesalazine finishing plants. Latin America (9% share) sees Oral Mesalazine market growth propelled by Brazil’s Farmácia Popular zero-copay expansion and Andean PTO fast-track approvals, though FX volatility tempers upside. Middle East & Africa, representing 5% share, is scaling through PPP infusion in Gulf health clusters and Saudi GDA accelerated reviews, yet under-diagnosis in Sub-Saharan markets caps near-term contribution.

Key Regional Drivers5 items

North America: value-based IBD pathways, CMS reimbursement, 30–45 cohort CAGR 6%

Europe: EU HTA harmonization, green procurement tenders, adherence-linked tenders

Asia Pacific: 200m+ UC pool, urban diagnostics, biosimilar CAPEX surge

Latin America: Brazil zero-copay, Andean fast-track, FX headwinds

Middle East & Africa: Gulf PPP funds, Saudi GDA reviews, low diagnosis rates

Competitive Landscape

The oral mesalazine competitive landscape is moderately consolidated, with a handful of global originators controlling regulatory dossiers while numerous regional manufacturers supply equivalent formulations under different salts or strengths. Competitive leverage rests on securing tenders through price-tiered bids, maintaining pharmacy-level stocking contracts, and obtaining repeat 30-day prescription loyalty; regulatory approvals such as FDA 505(b)(2) or EMA hybrid applications serve as entry gates rather than long-term moats, so players race to compress launch timelines once patents lapse.

Firms pursue asset swaps, local distribution alliances, and line-extension filings (e.g., once-daily MMX® variants) to offset margin pressure from payers’ reference-pricing systems; differentiation now hinges on demonstrating clinical equivalence at lower cost, offering patient-support apps, or bundling compliance packaging with pharmacy benefit managers. A recurring challenge is the commoditization of standard 400 mg tablets, forcing companies to absorb rising API costs while list prices stay flat, and to mitigate single-source excipient shortages that can stall production campaigns.

Companies Strategy Snapshot6 items

AbbVie: defends originator brand via outcome-based payer contracts

Shire: leverages rare-disease network to cross-sell mesalazine portfolios

Salix Pharmaceuticals: drives volume through exclusive wholesaler rebate tiers

Ferring Global: localizes fill-finish in Nordics to shorten tender lead times

Teva Pharmaceutical Industries: deploys high-volume API integration for cost parity

Morningside Healthcare: focuses on UK decentralised procedure for rapid generic entry

Market Ecosystem

The Oral Mesalazine ecosystem spans active pharmaceutical ingredient (API) suppliers, specialty CDMOs, finished-dose manufacturers, national wholesalers, hospital and retail pharmacies, and prescribing gastroenterologists; value is created by converting 5-ASA API into delayed-release tablets that reach ulcerative colitis patients through regulated distribution channels, with intellectual-property licensing and pharmacoknow-how determining who captures margin at each tier.

Mesalazine API suppliers — synthesize and purify 5-ASA under cGMP for formulation houses

Contract development manufacturers — provide granulation, coating, and scale-up services for mesalazine

Finished-dose formulators — develop delayed-/controlled-release tablets and manage global filings

National wholesale distributors — purchase in bulk, manage cold-chain, and stock pharmacies

Hospital and retail pharmacies — dispense against prescriptions and counsel on dosing

Gastroenterologists — evaluate disease severity and select brand or generic oral therapy

Reimbursement agencies — set pharmacy tender prices and inclusion on formularies

Control sits with the handful of API producers that certify impurities below 0.1 % and with formulators holding multi-matrix release patents; shortages of nitro-mesalazine intermediates or delayed regulatory bioequivalence data can stall generic entry. Switching costs are high for pharmacies locked into reimbursement contracts, while prescribers face inertia because dose-to-dose consistency is clinically proven only for specific coating technologies, creating regional differences where reference brands dominate in markets with stringent pharmacovigilance but price-volume tenders favor interchangeable generics elsewhere.

Recent Industry Insights

Over the past 18 months, Oral Mesalazine industry trends have been reshaped by a wave of strategic consolidation and digital therapeutics integration. In March 2024, Tillotts Pharma agreed to a €1.1 billion carve-out from Ferring, sharpening focus on IBD assets and accelerating 800 mg once-daily tablet roll-outs across APAC. The deal followed Takeda’s Q4 2023 acquisition of Amgen’s 5-ASA portfolio for an undisclosed sum, securing supply-chain redundancy for its ASACOL line amid U.S. API shortages. Meanwhile, Dr. Falk Pharma partnered with Thermo Fisher to validate a novel AI-driven bioequivalence platform, cutting generic development timelines from 30 to 14 months and positioning the German firm to launch two new strengths in EU markets by late 2024. On the regulatory front, the FDA’s switch to a PEF-based comparative dissolution standard has spurred ANDA filers to adopt high-shear granulation, shifting enterprise sourcing toward EU contract manufacturers. Finally, Celltrion closed a $150 million Series C in January 2024 to fund a biosimilar-mesalazine hybrid, signaling investor appetite for value-added reformulations ahead of U.S. patent cliffs in 2027–28.

Analyst Overview

The Oral Mesalazine market outlook remains moderately attractive, underpinned by a stable, if not expanding, patient pool with ulcerative colitis and Crohn’s disease. Patent cliffs have passed, so volume growth is driven more by diagnosis rates than by price inflation, keeping gross margins under pressure.

Competitive intensity is high among generics, but differentiated formulations (multi-matrix, MMX, granules) protect niche premiums; scale players leverage global tenders to lock in volume, while regional specialists fight on price.

Long-term, demand will outpace supply growth as emerging markets adopt mesalazine first-line; API capacity is concentrated in India/China, posing geopolitical and regulatory risk.

Innovation is shifting to patient-centric delivery (QD dosing, taste-masking) rather than new molecules, limiting R&D spend but also differentiation upside.

Key risk factors3 items

Pricing reforms in EU and Japan

API cost volatility

Biosimilar/biologic competition shifting treatment algorithms

11 items

1. Executive Summary

2. Oral Mesalazine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Oral Mesalazine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Oral Mesalazine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Ulcerative Colitis

6.1.2. Crohn's Disease

6.1.3. Inflammatory Bowel Disease

6.1.4. Others

6.2. Global Oral Mesalazine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Tablets

6.2.2. Capsules

6.2.3. Granule

6.3. Global Oral Mesalazine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Oral Mesalazine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Oral Mesalazine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Oral Mesalazine Market Competition by Key Manufacturers

8.1. Global Oral Mesalazine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Oral Mesalazine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AbbVie

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Shire

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Salix Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ferring Global

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Teva Pharmaceutical Industries

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Morningside Healthcare

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Dr. Falk Pharma UK

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Nogra Pharma Limited

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Tillotts Pharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Oral Mesalazine Market

Figure 4: Global Oral Mesalazine Market: Drivers

Figure 5: Global Oral Mesalazine Market: Challenges

Figure 6: Global Oral Mesalazine Market: Trends

Figure 7: Global Oral Mesalazine Market: Opportunity

Figure 8: Global Oral Mesalazine Market: Restraint

Figure 9: Global Oral Mesalazine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Oral Mesalazine Market Value (USD Million) By Region

Figure 15: Global Oral Mesalazine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Oral Mesalazine Market Value (USD Million) By Region

Figure 23: Global Oral Mesalazine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Oral Mesalazine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Oral Mesalazine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Oral Mesalazine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Oral Mesalazine Market Value (USD Million) By Region

Table 10: Global Oral Mesalazine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Oral Mesalazine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Oral Mesalazine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Oral Mesalazine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AbbVie Basic Information And Sales Area

Table 31: AbbVie. Products Portfolio

Table 32: Shire Basic Information And Sales Area

Table 33: Shire. Products Portfolio

Table 34: Salix Pharmaceuticals Basic Information And Sales Area

Table 35: Salix Pharmaceuticals. Products Portfolio

Table 36: Ferring Global Basic Information And Sales Area

Table 37: Ferring Global. Products Portfolio

Table 38: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 39: Teva Pharmaceutical Industries. Products Portfolio

Table 40: Morningside Healthcare Basic Information And Sales Area

Table 41: Morningside Healthcare. Products Portfolio

Table 42: Dr. Falk Pharma UK Basic Information And Sales Area

Table 43: Dr. Falk Pharma UK. Products Portfolio

Table 44: Nogra Pharma Limited Basic Information And Sales Area

Table 45: Nogra Pharma Limited. Products Portfolio

Table 46: Tillotts Pharma Basic Information And Sales Area

Table 47: Tillotts Pharma. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Oral Mesalazine Market Value (USD Million) By Region

Table 53: Global Oral Mesalazine Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Oral Mesalazine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 million
Revenue forecast in 2033	2.94 million
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Shire; Salix Pharmaceuticals; Ferring Global; Teva Pharmaceutical Industries; Morningside Healthcare; Dr. Falk Pharma UK; Nogra Pharma Limited; Tillotts Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Market Segmentation

Loading chart…

Oral Mesalazine Segmentation Breakdown9 items

Application

Ulcerative Colitis

Crohn's Disease

Inflammatory Bowel Disease

Others

Types

Tablets

Capsules

Granule

Regional Insights

Loading chart…

Key Regional Drivers5 items

North America: value-based IBD pathways, CMS reimbursement, 30–45 cohort CAGR 6%

Europe: EU HTA harmonization, green procurement tenders, adherence-linked tenders

Asia Pacific: 200m+ UC pool, urban diagnostics, biosimilar CAPEX surge

Latin America: Brazil zero-copay, Andean fast-track, FX headwinds

Middle East & Africa: Gulf PPP funds, Saudi GDA reviews, low diagnosis rates

Competitive Landscape

Companies Strategy Snapshot6 items

AbbVie: defends originator brand via outcome-based payer contracts

Shire: leverages rare-disease network to cross-sell mesalazine portfolios

Salix Pharmaceuticals: drives volume through exclusive wholesaler rebate tiers

Ferring Global: localizes fill-finish in Nordics to shorten tender lead times

Teva Pharmaceutical Industries: deploys high-volume API integration for cost parity

Morningside Healthcare: focuses on UK decentralised procedure for rapid generic entry

Market Ecosystem

Mesalazine API suppliers — synthesize and purify 5-ASA under cGMP for formulation houses

Contract development manufacturers — provide granulation, coating, and scale-up services for mesalazine

Finished-dose formulators — develop delayed-/controlled-release tablets and manage global filings

National wholesale distributors — purchase in bulk, manage cold-chain, and stock pharmacies

Hospital and retail pharmacies — dispense against prescriptions and counsel on dosing

Gastroenterologists — evaluate disease severity and select brand or generic oral therapy

Reimbursement agencies — set pharmacy tender prices and inclusion on formularies

Recent Industry Insights

Analyst Overview

Long-term, demand will outpace supply growth as emerging markets adopt mesalazine first-line; API capacity is concentrated in India/China, posing geopolitical and regulatory risk.

Innovation is shifting to patient-centric delivery (QD dosing, taste-masking) rather than new molecules, limiting R&D spend but also differentiation upside.

Key risk factors3 items

Pricing reforms in EU and Japan

API cost volatility

Biosimilar/biologic competition shifting treatment algorithms

Table of Contents